This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

GSK586529

GlaxoSmithKline plc

Drug Names(s): GSK586529

Description: GSK586529 is a corticotropin releasing factor R1 (CRF1) receptor antagonist.

Deal Structure: In July 2001, Neurocrine and GSK entered into a worldwide research, development and commercialization agreement for CRF1 receptor antagonists to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression, and IBS.

Partners: Neurocrine Biosciences, Inc.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug